Page 15 - Pharma Sector News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The pharmaceutical sector in India is showing strong domestic growth of 7% to 9%, despite flat global growth in the US and Europe, according to pharma expert Kewal Handa. He sees good opportunities for Indian companies in the US, as a significant number of patents are set to expire in the next five years. Biosimilars and the application of artificial intelligence in R&D are expected to be major growth areas, and Handa predicts double-digit growth next year.

Except for Pharma and Realty, all sectors ended in the red. Pharma sector saw huge buying interest on the back of good results announced by Cipla and Dr. Reddy, along with a couple of USFDA approval...

There are reports that PE firms Blackstone and Baring Asia, among others, are in talks with Cipla for buying stakes in the company. If the deal goes through, analysts say it will present a greater expanse for growth for one of India's leading drug makers

The growing positivity around Lupin is clearly demonstrated in the stock’s performance, which has spiked over 38 percent since the start of April. However, some analysts believe the valuation is a bit stretched.

A delayed monsoon and reduced demand for acute products impacted the industry briefly, but analysts expect the sector to sustain double-digit growth figures for the year.